Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Darinaparsin

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Solasia Pharma: DARVIAS Injection 135mg Approved in Japan
    Solasia Pharma: DARVIAS Injection 135mg Approved in Japan

    19 Jun 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220620005030/en

    BUSINESSWIRE
    19 Jun 2022
    Share Share
    Solasia, Nippon Kayaku Partner in Japan for DARINAPARSIN (SP-02)
    Solasia, Nippon Kayaku Partner in Japan for DARINAPARSIN (SP-02)

    26 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211026005660/en

    BUSINESSWIRE
    26 Oct 2021
    Share Share
    Solasia announces the filing of a new regulatory filing for DARINAPARSIN
    Solasia announces the filing of a new regulatory filing for DARINAPARSIN

    30 Jun 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210630006008/de

    BUSINESSWIRE
    30 Jun 2021
    Share Share
    Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study
    Solasia Announces Positive Results of DARINAPARSIN in Pivotal Phase 2 Study

    14 Jun 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200615005228/en

    BUSINESSWIRE
    14 Jun 2020
    Share Share